Creative Biolabs advances glycoprotein development, supporting safer, more effective biopharmaceuticals through cutting-edge glycobiology platforms.
SHIRLEY, NY, August 30, 2025 /24-7PressRelease/ — In the deeper waters of life sciences, glycobiology is gradually becoming a norm. As antibody drugs, vaccines, and cell therapies move forward, the glycan chain structure and analysis have become central to drug safety, efficacy, and stability. Therapeutic glycoprotein development and precise analysis of carbohydrate structures are no longer technical niceties—they’re strategic imperatives driving the next-generation biopharmaceutical innovation.
Glycoproteins—protein molecules linked by carbohydrate molecules—are far more than mere cosmetic compounds. Their states of glycosylation have profound effects on biological function, including protein stability, immunogenicity, and pharmacokinetics. Defucosylation of antibodies, for example, can highly enhance ADCC activity, which increases anti-tumor effect, and increased sialylation can increase serum half-life and therapeutic effect.
Creative Biolabs’ glycoprotein platform continues the trend by engineering various specific cell lines (e.g., HighSialo-Cell and Fuco-Cell) to allow precise control of glycosylation. Such a “customization on demand” capability is exactly the technical support biopharmaceutical companies currently need for antibody engineering and protein drug development.
“Doubtless, the structural complexity of the glycan molecules is much higher than that of proteins or nucleic acids. Their branching, character of connections, and modifications are very changeable, and it is difficult to read them. Traditional methods are not generally able to rise to the challenge, but the new analysis techniques are gradually closing this gap,” according to a scientist at Creative Biolabs.
Scientists at Creative Biolabs provide a full scale of carbohydrate analysis services using the most recent technology, such as HPAE-PAD, CE, and UHPLC-MS. These instruments enable accurate quantitation and structural elucidation of monosaccharides and oligosaccharides that are significant in drug development, vaccine design, and biomarker discovery.
Parallel with this, polysaccharides are gaining more attention for their bioactivities, including antioxidant, anti-inflammatory, and immunomodulatory activities. With the growing need for biomaterials and nature therapeutics, the investigation of polysaccharide structure-function relationships is more significant than ever before.
This company’s polysaccharide analysis platform combines SEC, NMR, and MS/MS to deliver deep molecular weight distribution, structure domain, and sulfation pattern insights. They can cover heparin derivatives, chitosan, starch, and more—both pharma and industrial R&D.
“From the design of glycoproteins to the profiling of polysaccharides, glycobiology is moving off the lab bench and onto the production floor. Our integrated platforms allow researchers and manufacturers to transform molecular complexity into therapeutic clarity,” said the scientist.
For additional information on therapeutic glycoprotein development solutions, visit https://www.creative-biolabs.com/glycoprotein/.
About Creative Biolabs
Creative Biolabs is a globally recognized biotech company that specializes in glycoprotein engineering, antibody discovery, and carbohydrate analysis. Having advanced platforms and experienced personnel, they empower researchers from around the globe in drug discovery and therapeutic development innovation in academic and industrial environments.
—
For the original version of this press release, please visit 24-7PressRelease.com here
